SCHEMBL21848352

SCHEMBL21848352

O=C(C=NO)Nc1ccc(Br)c(F)c1

nearest known ligand 0.61

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.61
KMT2A Q03164 2/20 0.61
CYP1A2 P05177 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
MAPT P10636 2/20 0.49
TP53 P04637 1/20 0.45
MAOB P27338 1/20 0.45
MAPK1 P28482 1/20 0.42
IDO1 P14902 1/20 0.42
ACHE P22303 9/20 0.40
KIF11 P52732 1/20 0.40
EGFR P00533 1/20 0.39
NPC1 O15118 1/20 0.39
NFKB1 P19838 1/20 0.39
RAB9A P51151 1/20 0.39
NFKB2 Q00653 1/20 0.39
RELA Q04206 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21848350 1.00 MEN1 (0.61) MEN1KMT2ACYP1A2NPSR1MAPT
SCHEMBL31544172 1.00 MEN1 (0.61) MEN1KMT2ACYP1A2NPSR1MAPT
SCHEMBL4091794 0.88 MEN1 (0.61) MEN1KMT2ACYP1A2NPSR1MAPT
SCHEMBL29700071 0.88 MEN1 (0.61) MEN1KMT2ACYP1A2NPSR1MAPT
SCHEMBL2728504 0.88 MEN1 (0.61) MEN1KMT2ACYP1A2NPSR1MAPT
SCHEMBL2728508 0.88 MEN1 (0.61) MEN1KMT2ACYP1A2NPSR1MAPT
SCHEMBL10578566 0.85 MEN1 (0.67) MEN1KMT2ACYP1A2NPSR1MAPT
SCHEMBL10578571 0.85 MEN1 (0.67) MEN1KMT2ACYP1A2NPSR1MAPT
SCHEMBL24576668 0.81 KMT2A (0.61) MEN1KMT2ACYP1A2NPSR1MAPT
SCHEMBL3531035 0.81 KMT2A (0.61) MEN1KMT2ACYP1A2NPSR1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3640247-B1 SYK INHIBITOR AND USE METHOD THEREFOR CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) 2022-01-12 EP disclosed
US-11091460-B2 Syk inhibitor and use method therefor CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2021-08-17 US disclosed
CN-110678461-B Syk inhibitors and methods of use thereof 正大天晴药业集团股份有限公司 2021-08-10 CN disclosed
US-20200199101-A1 SYK INHIBITOR AND USE METHOD THEREFOR CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2020-06-25 US disclosed
EP-3640247-A1 SYK INHIBITOR AND USE METHOD THEREFOR Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) 2020-04-22 EP disclosed
CN-110678461-A Syk inhibitors and methods of use thereof 正大天晴药业集团股份有限公司 2020-01-10 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11091460-B2 Syk inhibitor and use method therefor SYK, BTK, LCK MEN1 2761/4885KMT2A 1592/4885CYP1A2 2692/4885
US-20200199101-A1 SYK INHIBITOR AND USE METHOD THEREFOR SYK, BTK, LCK MEN1 2761/4885KMT2A 1592/4885CYP1A2 2692/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.